T-20 access programme to continue in UK for a further two months

The programme providing access to T-20 prior to market approval was originally scheduled to run from November 2002 to March 2003.

However, Roche has announced that it will be extending this for a further two months “to tide us over to launch of T-20, which is expected [in Europe] in late May/June 2003”. Criteria and logistics remain the same for this extended time period and includes a commitment to provide free drug during this period and until one month after launch. Any patient resident in the UK is eligible for consideration.

Anyone interested in more information on this programme or wishing to register a patient should call Julia Nicholson on 01707 6234.